1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,050 | 1,170 | 21.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT ALL SUBJECTS IN PHASE I SAD STUDY OF LAE102 HAVE BEEN DOSED FOR THE TREATMENT OF OBESITY | 3 | HKEx | ||
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 28.11. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT IND-ENABLING STUDY INITIATED FOR LAE123 FOR THE TREATMENT OF SEVERE DISEASES | 1 | HKEx | ||
| 27.11. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.11. | LAEKNA-B (02105): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 21.11. | Laekna partners with Lilly to develop obesity therapy | 4 | Pharmaceutical Business Review | ||
| 21.11. | LAEKNA-B (02105): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 20.11. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT CLINICAL COLLABORATION WITH LILLY ON LAE102 IN THE U.S. FOR THE TREATMENT OF OBESITY | 2 | HKEx | ||
| 18.10. | LAEKNA-B (02105): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 OCTOBER 2024 | 2 | HKEx | ||
| 18.10. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUBCUTANEOUS COHORT INITIATED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY | 2 | HKEx | ||
| 27.09. | LAEKNA-B (02105): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.09. | LAEKNA-B (02105): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.09. | LAEKNA-B (02105): (1) PROPOSED GRANT OF RSUS TO DIRECTORS UNDER THE 2024 SHARE AWARD SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 05.09. | LAEKNA-B (02105): GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 26.08. | LAEKNA-B (02105): INTERIM REPORT 2024 | - | HKEx | ||
| 16.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 06.08. | LAEKNA-B (02105): DATE OF BOARD MEETING | 1 | HKEx | ||
| 26.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY | 1 | HKEx | ||
| 23.05. | Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer | 107 | PR Newswire | SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the... ► Artikel lesen | |
| 04.01. | Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 | 174 | PR Newswire | Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis.
Derived from the platform, LAE105 is a potentially... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Qiagen NV-Aktie läuft heute schlechter (42,62 €) | Im Minus liegt aktuell der Anteilsschein von Qiagen NV . Die Aktie kostete zuletzt 42,62 Euro. Am Aktienmarkt hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,62 Prozent verbilligt.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen LAEKNA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,030 Euro und damit -0,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAEKNA INC finden Sie auf Wallstreet Online.
